Therefore, the combination of Nano-FdUMP/Nano-Folox and anti-PD-L1 mAb will potentially achieve a superior outcome for CRC patients (particularly for MSS ones, up to 85% of total population) at advanced stages. Here, CD274 is linked to colorectal carcinoma.